SCHEMBL23779121

SCHEMBL23779121

CS(=O)(=O)Nc1cc2n(n1)CCN(C(=O)c1cc3ccccc3[nH]1)C2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 1/20 0.54
▸ HRH4 Q9H3N8 6/20 0.52
▸ CA12 O43570 1/20 0.48
▸ CA1 P00915 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ CA7 P43166 1/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ HRH3 Q9Y5N1 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ ADRA2A P08913 1/20 0.46
▸ ADORA3 P0DMS8 1/20 0.46
▸ CHRM1 P11229 1/20 0.46
▸ MAOA P21397 1/20 0.46
▸ TBXA2R P21731 1/20 0.46
▸ OPRM1 P35372 1/20 0.46
▸ MDH1 P40925 1/20 0.46
▸ KCNH2 Q12809 1/20 0.46
▸ ABCG2 Q9UNQ0 1/20 0.46
▸ MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23779051 0.90 HRH4 (0.53) HDAC6HRH4CA12CA1CA2
SCHEMBL24321164 0.90 HDAC6 (0.49) HDAC6HRH4CA12CA1CA2
SCHEMBL23779103 0.89 HDAC6 (0.50) HDAC6HRH4CA12CA1CA2
SCHEMBL23779094 0.88 HDAC6 (0.48) HDAC6HRH4CA12CA1CA2
SCHEMBL24321133 0.87 HRH4 (0.50) HDAC6HRH4CA12CA1CA2
SCHEMBL23779079 0.86 HDAC6 (0.48) HDAC6HRH4CA12CA1CA2
SCHEMBL23779086 0.86 HRH4 (0.54) HDAC6HRH4CA12CA1CA2
SCHEMBL23779046 0.85 HDAC6 (0.49) HDAC6HRH4CA12CA1CA2
SCHEMBL23779101 0.85 POLB (0.51) HDAC6HRH4CA12CA1CA2
SCHEMBL23779117 0.84 HRH4 (0.52) HDAC6HRH4CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220081444-A1 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AICURIS GMBH & CO. KG (DE) 2022-03-17 — — US disclosed
US-20220081444-A1 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AICURIS GMBH & CO. KG (DE) 2022-03-17 — — US disclosed
EP-3873910-A1 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AiCuris GmbH & Co. KG (DE) 2021-09-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220081444-A1 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) HCCS, CDK2, BRD4 HDAC6 897/4885HRH4 1121/4885CA12 4017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback